Page last updated: 2024-11-04

methocarbamol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Methocarbamol is a muscle relaxant that works by blocking nerve impulses in the brain that are responsible for muscle spasms. It is typically used to treat muscle pain and spasms associated with injuries, strains, and other conditions. The drug was first synthesized in 1956 and was initially marketed as a tranquilizer. However, it was later found to be more effective as a muscle relaxant. Methocarbamol is available as a generic medication and is typically taken by mouth. It can also be administered intravenously or intramuscularly. Common side effects of methocarbamol include drowsiness, dizziness, and weakness. It is important to note that methocarbamol can interact with other medications, so it is important to talk to your doctor before taking it. Methocarbamol is studied to understand its mechanisms of action, its efficacy in treating various conditions, and its safety profile. Research is ongoing to explore potential alternative uses for methocarbamol, such as in the treatment of pain associated with cancer and other chronic conditions.'

Methocarbamol: A centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

methocarbamol : A racemate comprising equimolar amounts of (R)- and (S)-methocarbamol. A centrally acting skeletal muscle relaxant, it is used as an adjunct in the short-term symptomatic treatment of painful muscle spasm. The (R)-enantiomer is more active than the (S)-enantiomer. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate : A carbamate ester that is glycerol in which one of the primary alcohol groups has been converted to its 2-methoxyphenyl ether while the other has been converted to the corresponding carbamate ester. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4107
CHEMBL ID1201117
CHEBI ID77498
CHEBI ID6832
SCHEMBL ID34365
MeSH IDM0013584

Synonyms (211)

Synonym
MLS001148605
AB00052040-15
BRD-A31521121-001-05-8
delaxin
1, 3-(o-methoxyphenoxy)-, 1-carbamate
parabaxin
532-03-6
metocarbamol
1, 3-(2-methoxyphenoxy)-, 1-carbamate
perilax
metofenia
glycerylguajacol-carbamat
nsc170960
relestrid
3-(o-methoxyphenoxy)-2-hydroxypropyl carbamate
miolaxene
miowas
robaxan
tresortil
miorilas
glycerylguaiacolate carbamate
robaxin
etroflex
guiacol-gliceriletere monocarbammato
methocarbamol
robaxine
methocal
ahr 85
robinax
robaxon
3-(2-methoxyphenoxy)-1-glyceryl carbamate
reflexyn
myolaxene
romethocarb
nsc-170960
metocarbamolo
lumirelax
3-(o-methoxyphenoxy)-1,2-propanediol 1-carbamate
2-hydroxy-3-(o-methoxyphenoxy)propyl 1-carbamate
wln: zvo1yq1or bo1
neuraxin
guaiacol glyceryl ether carbamate
avetil
surquetil
guaiphenesine carbamate
1,2-propanediol, 3-(2-methoxyphenoxy)-, 1-carbamate
smr000058719
MLS000028610 ,
KBIO1_000434
DIVK1C_000434
2-hydroxy-3-{[2-(methyloxy)phenyl]oxy}propyl carbamate
3967-43-9
SPECTRUM_000997
PRESTWICK3_000184
PRESTWICK_614
NCGC00016492-01
cas-532-03-6
IDI1_000434
SPECTRUM5_000956
PRESTWICK2_000184
metofenina
forbaxin
methocarbamolum [inn-latin]
robaxin-750
robaxisol
metocarbamolo [dcit]
metocarbamol [inn-spanish]
carbamic acid, 2-hydroxy-3-(o-methoxyphenoxy)propyl ester
guaiphenesin carbamate
brn 1884446
(+-)-3-(o-methoxyphenoxy)-1,2-propanediol 1-carbamate
nsc 170960
hsdb 3122
einecs 208-524-3
1,2-propanediol, 3-(o-methoxyphenoxy)-, 1-carbamate
AB00052040
DB00423
(rs)-2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate
methocarbamol (jan/usp/inn)
robaxin (tn)
delaxin (tn)
D00402
BSPBIO_000107
BPBIO1_000119
NCGC00089805-02
NCGC00089805-03
KBIO2_004045
KBIO2_006613
KBIOSS_001477
KBIO3_001491
KBIO2_001477
KBIOGR_000517
SPECTRUM3_000496
SPECTRUM4_000049
NINDS_000434
SPBIO_001264
SPECTRUM2_001272
PRESTWICK0_000184
PRESTWICK1_000184
SPBIO_002028
SPECTRUM1500397
BSPBIO_001991
HMS2091D14
AC-12037
CHEMBL1201117
chebi:77498 ,
HMS501F16
HMS1568F09
HMS1920L19
[2-hydroxy-3-(2-methoxyphenoxy)propyl] carbamate
NCGC00018257-04
NCGC00018257-02
NCGC00018257-03
HMS2095F09
HMS3259M17
carbamate, guaiphenesin
2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate
M2254
carbamic acid 2-hydroxy-3-(2-methoxyphenoxy)propyl ester
carbamic acid [2-hydroxy-3-(2-methoxy-phenoxy)-propyl] ester
A829442
nsc-757112
pharmakon1600-01500397
nsc757112
dtxcid503286
dtxsid6023286 ,
tox21_110454
robamol
traumacut
HMS2233G18
AKOS015960743
CCG-39655
FT-0671053
methocarbamolum
methocarbamol [usp:inn:ban:jan]
125od7737x ,
unii-125od7737x
FT-0628302
NCGC00018257-07
S1736
HMS3369B17
gtpl6829
(+/-)-3-(o-methoxyphenoxy)-1,2-propanediol 1-carbamate
methocarbamol [who-dd]
methocarbamol [vandf]
methocarbamol [usp monograph]
methocarbamol [inn]
methocarbamol [mi]
methocarbamol [green book]
1,2-propanediol, 3-(2-methoxyphenoxy)-, 1-carbamate, (+/-)-
methocarbamol component of robaxisal
methocarbamol [mart.]
methocarbamol [hsdb]
methocarbamol [jan]
methocarbamol [usp-rs]
robaxisal component methocarbamol
methocarbamol [orange book]
HY-B0262
NC00509
SCHEMBL34365
NCGC00018257-08
tox21_110454_1
methyocarbamol
GNXFOGHNGIVQEH-UHFFFAOYSA-N
robaxisol (salt/mix)
2-hydroxy-3-(o-methoxyphenoxy)propyl carbamate
2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate #
3-o-(2-methoxyphenyl)-1-glyceryl carbamate
AB00052040_17
OPERA_ID_1471
AB00052040_16
mfcd00057662
sr-01000000240
SR-01000000240-2
methocarbamol, united states pharmacopeia (usp) reference standard
guaiacol glyceryl ether carbamate, analytical standard
HMS3655O06
methocarbamol, pharmaceutical secondary standard; certified reference material
3-(2-methoxyphenoxy)-1,2-propanediol 1-carbamate
SR-01000000240-3
SBI-0051442.P003
HMS3712F09
SW196781-3
Q411456
methocarbamol (robaxin)
methocarbamol,(s)
AS-11691
BCP13801
D70323
NCGC00018257-16
SY035642
EN300-119525
Z1521553984
methocarbamolum (inn-latin)
robaxin-v injectable
methocarbamol (mart.)
methocarbamol tablets
methocarb 500-ezs
methocarbamol (usp-rs)
robaxin-v tablets
rac-2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate
m03ba03
methocarbamol tablets, usp, 500 mg
metocarbamol (inn-spanish)
methocarbamol (usp monograph)
(+-)-2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate
methocarbamol (usp:inn:ban:jan)
methcarbamol
methocarbamol granules dc 90%
methocarbamol tablets, usp, 750 mg
chebi:6832

Research Excerpts

Overview

Methocarbamol is a muscle relaxant that can be used in equines to treat symptoms associated with Rhabdomyolysis. It is a carbamate derivative used as a muscle Relaxant with sedative effects.

ExcerptReferenceRelevance
"Methocarbamol seems to be a promising safe and well-tolerated medication, and plays a role in the treatment of muscle cramps in patients with liver cirrhosis."( Randomized-controlled trial of methocarbamol as a novel treatment for muscle cramps in cirrhotic patients.
Abd-Elsalam, S; Arafa, M; Badawi, R; Elfert, A; Elkadeem, M; Elkhalawany, W; Soliman, S, 2019
)
2.24
"Methocarbamol is a muscle relaxant that can be used in equines to treat symptoms associated with Rhabdomyolysis."( Methocarbamol suspension for the treatment of rhabdomyolysis in equines.
Pruitt, BN,
)
2.3
"Methocarbamol is a skeletal muscle relaxant and is widely used to relieve pain in muscles. "( Interaction of methocarbamol and yeast sucrase induces enzyme inhibition.
Alavi, S; Asghari, M; Lotfi, L; Masoudnia, A; Minai-Tehrani, D; Osmani, R; Pirsalehi, M; Sobhani-Damavandifar, Z, 2012
)
2.17
"Methocarbamol is a carbamate derivative used as a muscle relaxant with sedative effects."( A fatal interaction of methocarbamol and ethanol in an accidental poisoning.
Ferslew, KE; Hagardorn, AN; McCormick, WF, 1990
)
1.31

Effects

ExcerptReferenceRelevance
"Methocarbamol has been oxidized in buffered solutions at the developed MMT-Ca-modified CPE in a single 2-electron irreversible anodic peak."( Electrochemical determination of methocarbamol on a montmorillonite-Ca modified carbon paste electrode in formulation and human blood.
El-Desoky, HS; Ghoneim, EM, 2010
)
1.36

Toxicity

ExcerptReferenceRelevance
" Outcome was favorable in both cats and no adverse effects were noted from the ILE."( Adjunctive therapy with intravenous lipid emulsion and methocarbamol for permethrin toxicity in 2 cats.
Kuo, K; Odunayo, A,
)
0.38
" No adverse events were observed with respect to DDN."( Deep dry needling of trigger points located in the lateral pterygoid muscle: Efficacy and safety of treatment for management of myofascial pain and temporomandibular dysfunction.
Gonzalez-Perez, LM; Granados-Nunez, M; Infante-Cossio, P; Lopez-Martos, R; Ruiz-Canela-Mendez, P; Urresti-Lopez, FJ, 2015
)
0.42

Pharmacokinetics

The hemodynamic, respiratory, and behavioral effects of methocarbamol were determined in horses. In a pharmacokinetic study, 15, 30, 60, and 150 mg kg-1 intravenous and oral doses were administered to rats.

ExcerptReferenceRelevance
"In a pharmacokinetic study, 15, 30, 60, and 150 mg kg-1 intravenous and oral doses of methocarbamol were administered to rats."( Pharmacokinetics and bioavailability of methocarbamol in rats.
Menargues, A; Nomen, M; Obach, R; Pruñonosa, J; Vallès, J,
)
0.62
"The hemodynamic, respiratory, and behavioral effects, as well as the pharmacokinetic properties of methocarbamol, were determined in horses."( Pharmacologic and pharmacokinetic properties of methocarbamol in the horse.
Ashcraft, S; Muir, WW; Sams, RA, 1984
)
0.74
" administration; the terminal elimination half-life ranged from 59 to 90 mins."( The pharmacology and pharmacokinetics of high-dose methocarbamol in horses.
Ashcraft, S; Muir, WW; Sams, RA, 1992
)
0.54
" The aim of this work was to develop and validate a new sensitive and reproducible isocratic reversed phase HPLC-UV detection method for simultaneous determination of MET and PAR in human plasma for the routine use in a therapeutic drug monitoring and pharmacokinetic laboratories."( Simultaneous determination of paracetamol and methocarbamol in human plasma By HPLC using UV detection with time programming: application to pharmacokinetic study.
El-Bedaiwy, HM; Helmy, SA, 2014
)
0.66
" Blood samples were collected at various times, concentrations of MCBL and PBZ measured using LC-MS/MS and pharmacokinetic parameters calculated using compartmental analysis."( Pharmacokinetics of methocarbamol and phenylbutazone in exercised Thoroughbred horses.
Kass, PH; Knych, HK; McKemie, DS; Seminoff, KN; Stanley, SD, 2016
)
0.76

Compound-Compound Interactions

ExcerptReferenceRelevance
"Methadone and buprenorphine have pharmacologic properties that are concerning for a high risk of drug-drug interactions (DDIs)."( Identifying Clinically Relevant Drug-Drug Interactions With Methadone and Buprenorphine: A Translational Approach to Signal Detection.
Acton, EK; Bilker, WB; Brensinger, CM; Dawwas, GK; Hennessy, S; Leonard, CE; Li, L; Miano, TA; Neuman, M; Nguyen, TPP; Soprano, SE; Wang, L; Woody, G; Yu, E, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
" Estimated bioavailability ranged between 77 and 112 per cent."( Pharmacokinetics and bioavailability of methocarbamol in rats.
Menargues, A; Nomen, M; Obach, R; Pruñonosa, J; Vallès, J,
)
0.4
" Peak plasma methocarbamol concentrations following oral administration occurred within 15 to 45 mins and oral bioavailability ranged from 50."( The pharmacology and pharmacokinetics of high-dose methocarbamol in horses.
Ashcraft, S; Muir, WW; Sams, RA, 1992
)
0.9
" Bioavailability of orally administered MCBL was characterized by a median (range) of 54."( The pharmacokinetics of methocarbamol and guaifenesin after single intravenous and multiple-dose oral administration of methocarbamol in the horse.
Colahan, P; Rumpler, MJ; Sams, RA, 2014
)
0.71
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

A reverse phase liquid chromatographic method was developed for determining methocarbamol in injection and tablet dosage forms.

ExcerptRelevanceReference
"A reverse phase liquid chromatographic method was developed for determining methocarbamol in injection and tablet dosage forms."( Liquid chromatographic determination of methocarbamol in injection and tablet dosage forms: collaborative study.
Everett, RL,
)
0.63
" In two of the five patients who complained of drowsiness, it disappeared upon reduction of dosage and did not reappear when original dosage was reinstituted."( Use of methocarbamol in orthopedics.
LEWIS, WB, 1959
)
0.69
"A new simple, rapid and sensitive reversed-phase liquid chromatographic method was developed and validated for the simultaneous determination of methocarbamol (MET) and aspirin (ASP) in their combined dosage form."( Simultaneous determination of methocarbamol and aspirin by RP-HPLC using fluorescence detection with time programming: its application to pharmaceutical dosage form.
Eid, M; El-Din, MS; Zeid, AM,
)
0.62
" Both methods were applied successfully for the determination of the selected drugs in their combined dosage form."( Smart manipulation of ratio spectra for resolving a pharmaceutical mixture of Methocarbamol and Paracetamol.
Abd-El Rahman, MK; Essam, HM, 2015
)
0.65
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
carbamate esterAny ester of carbamic acid or its N-substituted derivatives.
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency33.49150.006038.004119,952.5996AID1159521
EWS/FLI fusion proteinHomo sapiens (human)Potency0.03720.001310.157742.8575AID1259253
GVesicular stomatitis virusPotency12.30180.01238.964839.8107AID1645842
chromobox protein homolog 1Homo sapiens (human)Potency56.23410.006026.168889.1251AID540317
survival motor neuron protein isoform dHomo sapiens (human)Potency0.79430.125912.234435.4813AID1458
Interferon betaHomo sapiens (human)Potency12.30180.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency12.30180.01238.964839.8107AID1645842
TAR DNA-binding protein 43Homo sapiens (human)Potency1.25891.778316.208135.4813AID652104
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency12.30180.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency12.30180.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (85)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (33)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (35)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (101)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1136300Acute toxicity in po dosed mouse assessed as concentration required to produce 50% loss of righting reflex administered as qd for 4 days measured for 1 min post last dose1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Pyrrolidinylideneureas, a new class of central nervous system agents.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1136299Anticonvulsant activity in po dosed mouse assessed as blockade of supramaximal electroshock-induced toxic seizure1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Pyrrolidinylideneureas, a new class of central nervous system agents.
AID1136307Blockade of pentylenetetrazol-induced lethality in po dosed mouse assessed as prolongation of death time1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Pyrrolidinylideneureas, a new class of central nervous system agents.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1136319Therapeutic index, ratio of PD50 for acute toxicity in po dosed mouse assessed as concentration required to produce 50% loss of righting reflex to MED25 for muscle relaxant activity in po dosed mouse assessed as increase in strychnine-induced persistant c1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Pyrrolidinylideneureas, a new class of central nervous system agents.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1136302Ratio of LD50 for po dosed mouse to PD50 for acute toxicity in po dosed mouse assessed as concentration required to produce 50% loss of righting reflex1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Pyrrolidinylideneureas, a new class of central nervous system agents.
AID1136287Muscle relaxant activity in po dosed mouse assessed as blockade of pentylenetetrazol-induced tonic extensor seizure1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Pyrrolidinylideneureas, a new class of central nervous system agents.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1136318Therapeutic index, ratio of PD50 for acute toxicity in po dosed mouse assessed as concentration required to produce 50% loss of righting reflex to MED20 for anticonvulsant activity in po dosed mouse assessed as blockade of supramaximal electroshock-induce1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Pyrrolidinylideneureas, a new class of central nervous system agents.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678721Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1136308Sedative activity in po dosed mouse assessed as increase in pentylenetetrazol-induced pseudo-convulsive threshold1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Pyrrolidinylideneureas, a new class of central nervous system agents.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1136286Antianxiety activity in ip dosed rat assessed as effect on increase in punished responses administered qd for 5 days measured every day for 5 days1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Pyrrolidinylideneureas, a new class of central nervous system agents.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1136301Acute toxicity in po dosed mouse assessed as mortality administered as qd for 6 days measured on day 7 post last dose1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Pyrrolidinylideneureas, a new class of central nervous system agents.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1136317Therapeutic index, ratio of PD50 for acute toxicity in po dosed mouse assessed as concentration required to produce 50% loss of righting reflex to MED20 for muscle relaxant activity in po dosed mouse assessed as blockade of pentylenetetrazol-induced tonic1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Pyrrolidinylideneureas, a new class of central nervous system agents.
AID1136298Muscle relaxant activity in po dosed mouse assessed as increase in strychnine-induced persistant convulsive threshold1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Pyrrolidinylideneureas, a new class of central nervous system agents.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1345928Human carbonic anhydrase 1 (4.2.1.1 Carbonate dehydratases)2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (240)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990135 (56.25)18.7374
1990's19 (7.92)18.2507
2000's10 (4.17)29.6817
2010's49 (20.42)24.3611
2020's27 (11.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 119.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index119.09 (24.57)
Research Supply Index5.67 (2.92)
Research Growth Index4.84 (4.65)
Search Engine Demand Index220.09 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (119.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials24 (9.02%)5.53%
Reviews8 (3.01%)6.00%
Case Studies22 (8.27%)4.05%
Observational1 (0.38%)0.25%
Other211 (79.32%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (16)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Methocarbamol and Orphenadrine for Acute, Non-traumatic, Non-radicular Low Back Pain: A Randomized, Placebo Controlled, 3-armed Study [NCT02665286]Phase 4240 participants (Actual)Interventional2016-03-31Completed
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel Group Study of the Efficacy and Safety of a Single Administration of F14 for Postoperative Analgesia in Patients Undergoing Unilateral Total Knee Replacement [NCT05603832]Phase 3151 participants (Actual)Interventional2022-11-17Active, not recruiting
"Study of the Effects of Serum and Follicular Fluid Relaxin Levels on Ovarian Function in IVF Cycles as a Part of the Project Relaxifert " [NCT04458454]11 participants (Actual)Observational2019-12-02Completed
Nonopioid Pain Control Regimen After Arthroscopic Hip Procedures [NCT05076110]Phase 4188 participants (Anticipated)Interventional2022-04-07Recruiting
Efficacy and Safety of Different Dosage Regimens of the Combination Methocarbamol/Paracetamol in Acute Low Back Pain (LBP): MioPain Study [NCT05204667]Phase 4192 participants (Anticipated)Interventional2021-10-07Recruiting
Methocarbamol in Treatment of Muscle Cramps in Cirrhotic Patients [NCT02642874]Phase 3200 participants (Anticipated)Interventional2017-04-01Recruiting
A Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human Relaxin in the Treatment of Systemic Sclerosis With Diffuse Scleroderma [NCT00704665]Phase 3231 participants (Actual)Interventional1998-12-31Completed
[NCT00004380]Phase 21 participants Interventional1991-12-31Completed
A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Relaxin in Subjects With Acute Heart Failure [NCT00520806]Phase 2/Phase 31,161 participants (Actual)Interventional2007-10-31Completed
A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety of Recombinant Human Relaxin (rhRlx) in Subjects With Preeclampsia [NCT00333307]Phase 118 participants (Anticipated)Interventional2006-10-31Suspended
A Phase II Randomized, Double Blind, Placebo-Controlled Study of Recombinant Human Relaxin in Patients With Decompensated Congestive Heart Failure [NCT00406575]Phase 211 participants (Actual)Interventional2006-11-30Terminated
A Pilot Safety and Dose-Finding Trial of Intravenous Recombinant Human Relaxin (rhRlx) in Compensated Congestive Heart Failure [NCT00259116]Phase 218 participants Interventional2005-11-30Completed
Addition of Methocarbamol to Postoperative Multimodal Analgesic Regimen: A Prospective, Randomized Pilot Study [NCT05388929]Phase 4120 participants (Anticipated)Interventional2022-06-23Recruiting
Ketamine Infusion Therapy for the Management of Acute Pain in Adult Rib Fracture Patients [NCT02432456]Phase 4153 participants (Actual)Interventional2015-09-30Completed
Open-label, Single-group, Multicentre, Phase III Study to Confirm the Efficacy and Safety of IP-TN When Administered for 2 Weeks to Patients With Low Back Pain, Scapulohumeral Periarthritis, or Cervico-omo-brachial Syndrome Associated With Muscle Strain [NCT02831569]Phase 380 participants (Actual)Interventional2016-07-27Completed
Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure [NCT05100017]126 participants (Anticipated)Interventional2021-09-30Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT02432456 (9) [back to overview]Hallucination
NCT02432456 (9) [back to overview]Length of Stay
NCT02432456 (9) [back to overview]Oral Morphine Equivalent (Narcotic Usage)
NCT02432456 (9) [back to overview]Oral Morphine Equivalent (Narcotic Usage)
NCT02432456 (9) [back to overview]Oral Morphine Equivalent (Narcotic Usage) in Severely Injured
NCT02432456 (9) [back to overview]Regional Anesthesia Utilization
NCT02432456 (9) [back to overview]Respiratory Failure
NCT02432456 (9) [back to overview]Visual Analog Numeric Pain Score
NCT02432456 (9) [back to overview]Visual Analog Numeric Pain Score
NCT02665286 (4) [back to overview]Cases of Moderate or Severe LBP
NCT02665286 (4) [back to overview]Functional Impairment as Measured on the Roland Morris Disability Questionnaire
NCT02665286 (4) [back to overview]Medications--Patient Self Report of Medication Use
NCT02665286 (4) [back to overview]Patient Satisfaction With Treatment
NCT02831569 (2) [back to overview]Assessment of Pain Due to Low Back Pain, Scapulohumeral Periarthritis or Cervico-omo-brachial Syndrome After 2 Weeks of Treatment
NCT02831569 (2) [back to overview]Percentage of Patients With Drug-related Adverse Events [AEs]

Hallucination

Hallucinations were documented and confirmed by the treating medical team. (NCT02432456)
Timeframe: Total Index Hospitalization up to 365 days

,
InterventionParticipants (Count of Participants)
AdultElderly
Ketamine Infusion02
Placebo Infusion12

[back to top]

Length of Stay

Total hospital length of stay in days up to 365 days. (NCT02432456)
Timeframe: Total Index Hospitalization up to 365 days

,
Interventiondays (Median)
AdultElderly
Ketamine Infusion55
Placebo Infusion4.06

[back to top]

Oral Morphine Equivalent (Narcotic Usage)

This is an analysis of the narcotic utilization during the study. Oral Morphine Equivalents is a means of standardizing narcotic utilization given a multitude of different medications are utilized. Medications are standardized to units (milligrams) or oral morphine for a standardized comparison. (NCT02432456)
Timeframe: 12-24 hours post infusion

,
Interventionoral morphine equivalents (Median)
AdultElderly
Ketamine Infusion4521.3
Placebo Infusion45.030

[back to top]

Oral Morphine Equivalent (Narcotic Usage)

This is an analysis of the narcotic utilization during the study. Oral Morphine Equivalents is a means of standardizing narcotic utilization given a multitude of different medications are utilized. Medications are standardized to units (milligrams) or oral morphine for a standardized comparison. (NCT02432456)
Timeframe: 24-48 hours post infusion

,
Interventionoral morphine equivalents (Median)
AdultElderly
Ketamine Infusion69.025
Placebo Infusion6744

[back to top]

Oral Morphine Equivalent (Narcotic Usage) in Severely Injured

This is an analysis of the narcotic utilization during the study. Oral Morphine Equivalents is a means of standardizing narcotic utilization given a multitude of different medications are utilized. Medications are standardized to units (milligrams) or oral morphine for a standardized comparison. (NCT02432456)
Timeframe: Total Index Hospitalization up to 365 days

,
Interventionoral morphine equivalents (Median)
AdultElderly
Ketamine Infusion153.067.5
Placebo Infusion170.586.8

[back to top]

Regional Anesthesia Utilization

This is a measure of the Epidural Placement rates. Epidural placement was binary as in patient received or did not receive an epidural infusion catheter for supplemental pain management. (NCT02432456)
Timeframe: Total Index Hospitalization up to 365 days

,
Interventionparticipants (Number)
AdultElderly
Ketamine Infusion74
Placebo Infusion36

[back to top]

Respiratory Failure

Respiratory failure within this trial was defined by the need for unanticipated intubation and/or transfer to ICU for respiratory support. (NCT02432456)
Timeframe: Total Index Hospitalization up to 365 days

,
InterventionParticipants (Count of Participants)
AdultElderly
Ketamine Infusion20
Placebo Infusion30

[back to top]

Visual Analog Numeric Pain Score

Visual Analog Numeric Pain scores are reported as a single numeric score between 0 and 10. The more severe the pain the higher the number with 10 representing the most severe pain imaginable. (NCT02432456)
Timeframe: 12-24 hours post infusion

,
Interventionscore on a scale (Mean)
AdultElderly
Ketamine Infusion5.75.1
Placebo Infusion6.15.2

[back to top]

Visual Analog Numeric Pain Score

Visual Analog Numeric Pain scores are reported as a single numeric score between 0 and 10. The more severe the pain the higher the number with 10 representing the most severe pain imaginable. (NCT02432456)
Timeframe: 24-48 hours post infusion

,
Interventionscore on a scale (Mean)
AdultElderly
Ketamine Infusion5.65.1
Placebo Infusion5.84.4

[back to top]

Cases of Moderate or Severe LBP

Participants with moderate to severe low back pain after treatment as report on the following ordinal scale: severe, moderate, mild, or none (NCT02665286)
Timeframe: 1 week

InterventionParticipants (Count of Participants)
Placebo34
Orphenadrine26
Methocarbamol31

[back to top]

Functional Impairment as Measured on the Roland Morris Disability Questionnaire

"Change in Roland Morris Disability Questionnaire between baseline and 1 week.~The low back pain functional disability scale is the RMDQ. The RMDQ is a 24-item low back pain functional scale recommended for use in low back pain research.Higher scores signify greater low back-related functional impairment.0= no functional impairment, 24= severe functional impairment." (NCT02665286)
Timeframe: 1 week

Interventionunits on a scale (Mean)
Placebo10.9
Orphenadrine9.4
Methocarbamol8.1

[back to top]

Medications--Patient Self Report of Medication Use

Participants still using medication such as analgesics for LBP after treatment (NCT02665286)
Timeframe: 1 week

InterventionParticipants (Count of Participants)
Placebo42
Orphenadrine40
Methocarbamol50

[back to top]

Patient Satisfaction With Treatment

The number of participants with affirmative response to the following question: Do you want the same medication combination during a subsequent episode of LBP. This is a patient-centered outcome that allows each individual to determine the desirability of the intervention. (NCT02665286)
Timeframe: 1 week

InterventionParticipants (Count of Participants)
Placebo51
Orphenadrine53
Methocarbamol51

[back to top]

Assessment of Pain Due to Low Back Pain, Scapulohumeral Periarthritis or Cervico-omo-brachial Syndrome After 2 Weeks of Treatment

"The outcome measure presents percentage of patients who showed marked improvement or moderate improvement in low back pain and/or scapulohumeral periarthritis and/or cervico-omo-brachial syndrome after 2 weeks of treatment." (NCT02831569)
Timeframe: Post 2 weeks.

InterventionPercentage of participants (Number)
Loxoprofen Sodium/Methocarbamol [FDC]37.5

[back to top] [back to top]